Liyang Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Liyang Wang has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Christine Delon
Clinical Effectiveness Unit, Royal College of Surgeons of England, London, UK
3 shared publications - David Dodwell
Nuffield Department of Population Health, University of Oxford, Oxford, UK
3 shared publications - Jemma M. Boyle
Clinical Effectiveness Unit, Royal College of Surgeons of England, London, UK
3 shared publications Kieran Horgan
Dept of Breast Surgery, St James’s University Hospital, Leeds, UK
3 shared publicationsMark Verrill
Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne, UK
3 shared publicationsAdam E Frampton
Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK
2 shared publications
Latest Publications
- Open Access
How representative are responders to the english cancer patient experience survey of english breast cancer patients? A cohort study using linked national cancer patient experience survey and cancer registry data
Objective The annual National Cancer Patient Experience Survey (CPES) gives insights into the quality of care received by patients with cancer treated in the NHS. This study assesses how the sample of breast cancer (BC) patients who responded to CPES in England compares to the population diagnosed with breast cancer. Design Retrospective population-based cohort study, conducted as part of the National Audit of Primary Breast Cancer and the National Audit of Metastatic Breast Cancer. Setting National Cancer Patient Experience Survey (CPES) responses linked to National Cancer Registration data for BC patients (stage 0–4) diagnosed between 2015 and 2021. Participants 315 676 people diagnosed with BC 2015–2021. Primary and secondary outcome measures Logistic regression was used to assess the association between personal, disease, and clinical characteristics and the odds of responding to CPES. Results CPES responses were provided by 44 809 individuals,14.2% of breast cancer registration records. Most survey responses (69%) were from patients in their first year since diagnosis. Response rates were significantly lower among men (adjusted odds ratio (aOR) 0.79; CI 0.68 to 0.92; p=0.002), younger (18–39 years, aOR 0.51; CI 0.48 to 0.54; 9Conclusion People with breast cancer who return CPES questionnaires differ in their characteristics to the population of people diagnosed with breast cancer. CPES is a valuable tool for supporting quality improvement, but this study highlights the need for targeted strategies to increase participation among underrepresented groups.
Open AccessHow representative are responders to the english cancer patient experience survey of english breast cancer patients? A cohort study using linked national cancer patient experience survey and cancer registry data
Objective The annual National Cancer Patient Experience Survey (CPES) gives insights into the quality of care received by patients with cancer treated in the NHS. This study assesses how the sample of breast cancer (BC) patients who responded to CPES in England compares to the population diagnosed with breast cancer. Design Retrospective population-based cohort study, conducted as part of the National Audit of Primary Breast Cancer and the National Audit of Metastatic Breast Cancer. Setting National Cancer Patient Experience Survey (CPES) responses linked to National Cancer Registration data for BC patients (stage 0–4) diagnosed between 2015 and 2021. Participants 315 676 people diagnosed with BC 2015–2021. Primary and secondary outcome measures Logistic regression was used to assess the association between personal, disease, and clinical characteristics and the odds of responding to CPES. Results CPES responses were provided by 44 809 individuals,14.2% of breast cancer registration records. Most survey responses (69%) were from patients in their first year since diagnosis. Response rates were significantly lower among men (adjusted odds ratio (aOR) 0.79; CI 0.68 to 0.92; p=0.002), younger (18–39 years, aOR 0.51; CI 0.48 to 0.54; 9Conclusion People with breast cancer who return CPES questionnaires differ in their characteristics to the population of people diagnosed with breast cancer. CPES is a valuable tool for supporting quality improvement, but this study highlights the need for targeted strategies to increase participation among underrepresented groups.
- Open Access
- 15 July 2026
- Published by Elsevier in Cancer Epidemiology
- Vol. 104, 103159
Evaluating breast cancer surgery ascertainment in England’s routine healthcare data: A retrospective cohort study
- 15 July 2026
- Published by Elsevier in Cancer Epidemiology
- Vol. 104, 103159
Open AccessEvaluating breast cancer surgery ascertainment in England’s routine healthcare data: A retrospective cohort study
- Open Access
Age, patient experience and satisfaction with breast cancer care: a cohort study using linked national cancer patient experience survey and cancer registry data
Objective To examine whether satisfaction with information provision and involvement in decision-making among people with breast cancer (BC) treated in English hospitals was associated with age and other patient characteristics. Design Retrospective population-based cohort study, conducted as part of the National Audit of Primary Breast Cancer and the National Audit of Metastatic Breast Cancer. Setting National Cancer Patient Experience Survey (CPES) responses linked to National Cancer Registration data for BC patients (stage 0–4) diagnosed between 2017 and 2021. Participants 40 018 patients diagnosed with BC who responded to CPES between 2017 and 2021. Primary and secondary outcome measures Responses to questions about overall experience of care, satisfaction with information provision, involvement in decision-making and clinical nurse specialist (CNS) contact were examined. The relationships between responses, personal, disease and clinical characteristics were analysed using multivariable Poisson regression. Results 90% of patients rated their overall care as ≥8 out of 10 (0=very poor; 10=very good), decreasing to 82% for those aged Conclusion Most patients reported high satisfaction with their BC care. Satisfaction was consistently lower among younger people and those with advanced disease; this finding might partly reflect more complex pathways but requires further exploration, ideally in partnership with patients to codesign solutions. Actionable remedial strategies are proposed.
Open AccessAge, patient experience and satisfaction with breast cancer care: a cohort study using linked national cancer patient experience survey and cancer registry data
Objective To examine whether satisfaction with information provision and involvement in decision-making among people with breast cancer (BC) treated in English hospitals was associated with age and other patient characteristics. Design Retrospective population-based cohort study, conducted as part of the National Audit of Primary Breast Cancer and the National Audit of Metastatic Breast Cancer. Setting National Cancer Patient Experience Survey (CPES) responses linked to National Cancer Registration data for BC patients (stage 0–4) diagnosed between 2017 and 2021. Participants 40 018 patients diagnosed with BC who responded to CPES between 2017 and 2021. Primary and secondary outcome measures Responses to questions about overall experience of care, satisfaction with information provision, involvement in decision-making and clinical nurse specialist (CNS) contact were examined. The relationships between responses, personal, disease and clinical characteristics were analysed using multivariable Poisson regression. Results 90% of patients rated their overall care as ≥8 out of 10 (0=very poor; 10=very good), decreasing to 82% for those aged Conclusion Most patients reported high satisfaction with their BC care. Satisfaction was consistently lower among younger people and those with advanced disease; this finding might partly reflect more complex pathways but requires further exploration, ideally in partnership with patients to codesign solutions. Actionable remedial strategies are proposed.
- 31 January 2026
- Published by Elsevier in Clinical Oncology
- Vol. 52, 104070
The National Audit of Metastatic Breast Cancer (NAoMe): Sharing Key Findings and Recommendations From the 2025 State of the Nation Report
- 31 January 2026
- Published by Elsevier in Clinical Oncology
- Vol. 52, 104070
The National Audit of Metastatic Breast Cancer (NAoMe): Sharing Key Findings and Recommendations From the 2025 State of the Nation Report
- Open Access
- 1 January 2026
- Published by Wiley in The Breast Journal
- Vol. 2026 (1) , e5063047
Recurrence Rate Following Breast Conservation Surgery: A Retrospective Cohort Study
Background: Breast‐conserving surgery (BCS) has become the standard treatment for early‐stage breast cancer, offering oncological safety, better breast aesthetics, and enhanced health‐related quality of life. The optimal margins for BCS have been debated. However, evidence on the impact of margin widths greater than 0 mm for invasive breast cancer remains limited. Cambridge Breast Unit (CBU) has adopted a policy where a single margin of < 1 mm (not at ink) for invasive disease would be acceptable, provided the other three radial margins are ≥ 1 mm. Method: Retrospective cohort study analyzed 372 women who underwent BCS for invasive breast cancer at CBU between 2015 and 2016. Patients with pure ductal carcinoma in situ (DCIS), prior breast cancer treatment, or neoadjuvant chemotherapy were excluded. Clinical data, including patient demographics, tumor characteristics, margin status, and recurrence and survival outcomes, were extracted from electronic records. Results: At a median follow‐up of 5.2 years, the ipsilateral breast tumor recurrence (IBTR) rate was 1.6% (6/372) with an overall recurrence rate of 5.6% (21/372). No significant association was found between final resection margins and local or overall recurrence rates, nor was margin status correlated with breast cancer recurrence‐free survival. A total of 53 patients (14.2%) required additional surgeries due to margin status. By accepting a single radial margin < 1 mm, our margin policy reduced reoperations by 33%. Conclusion: Margin assessment in breast surgery is multifaceted, requiring a personalized approach that considers tumor biology, systemic treatments, and pathological variability. Our findings support accepting a margin width of < 1 mm (no tumor on ink) for a single radial margin in invasive breast cancer, provided the other three radial margins are ≥ 1 mm. It reduces reoperations without compromising oncological outcomes. Integrating advanced intraoperative techniques and multidisciplinary decision‐making will further optimize patient care and long‐term outcomes.
- 1 January 2026
- Published by Wiley in The Breast Journal
- Vol. 2026 (1) , e5063047
Open AccessRecurrence Rate Following Breast Conservation Surgery: A Retrospective Cohort Study
Background: Breast‐conserving surgery (BCS) has become the standard treatment for early‐stage breast cancer, offering oncological safety, better breast aesthetics, and enhanced health‐related quality of life. The optimal margins for BCS have been debated. However, evidence on the impact of margin widths greater than 0 mm for invasive breast cancer remains limited. Cambridge Breast Unit (CBU) has adopted a policy where a single margin of < 1 mm (not at ink) for invasive disease would be acceptable, provided the other three radial margins are ≥ 1 mm. Method: Retrospective cohort study analyzed 372 women who underwent BCS for invasive breast cancer at CBU between 2015 and 2016. Patients with pure ductal carcinoma in situ (DCIS), prior breast cancer treatment, or neoadjuvant chemotherapy were excluded. Clinical data, including patient demographics, tumor characteristics, margin status, and recurrence and survival outcomes, were extracted from electronic records. Results: At a median follow‐up of 5.2 years, the ipsilateral breast tumor recurrence (IBTR) rate was 1.6% (6/372) with an overall recurrence rate of 5.6% (21/372). No significant association was found between final resection margins and local or overall recurrence rates, nor was margin status correlated with breast cancer recurrence‐free survival. A total of 53 patients (14.2%) required additional surgeries due to margin status. By accepting a single radial margin < 1 mm, our margin policy reduced reoperations by 33%. Conclusion: Margin assessment in breast surgery is multifaceted, requiring a personalized approach that considers tumor biology, systemic treatments, and pathological variability. Our findings support accepting a margin width of < 1 mm (no tumor on ink) for a single radial margin in invasive breast cancer, provided the other three radial margins are ≥ 1 mm. It reduces reoperations without compromising oncological outcomes. Integrating advanced intraoperative techniques and multidisciplinary decision‐making will further optimize patient care and long‐term outcomes.